Table 2.
Treatment outcomes of Parkinson's disease patients that underwent MRgFUS treatment.
| Authors & year | Target | Patients, n | Motor UPDRS (Part II) | ||||
|---|---|---|---|---|---|---|---|
| Pretreatment | Post treatment 3 months |
Point reduction | Change (%) | Significance | |||
| Magara et al. 2014 Group 1 |
Pallidothalamic tract | 4 | 18.8∗ | 16.5 | 2.3 | 12.2 | NA |
| Magara et al. 2014 Group 2 |
Pallidothalamic tract | 9 | 18.7∗ | 7.3 | 11.4 | 61.0 | p < 0.001 |
| Schlesinger et al. 2015 | Thalamotomy | 7 | 27.0 | 19.7 | 7.3 | 27.0 | p = 0.036 |
| Na et al. 2015 | Pallidotomy | 1 | 10 | 5 | 5 | 50 | NA |
| Zaaroor et al. 2017 | Thalamotomy | 12∗∗ | 24.9 | 13.4∗∗∗ | 11.5 | 46.2 | p = 0.002 |
∗A modified, not validated version of the motor-UPDRS that scored only the treated side of the body to a maximal score of 56 instead of 108 points in the original scale.
∗∗Of the 12 patients in Zaaroor et al., 7 are the same patients as in Schlesinger et al.
∗∗∗UPDRS at 6 months.